Travere Therapeutics, Inc. TVTX Enterprise value

Enterprise value at other companies

Vertex PharmaceuticalsVRTX

$120.2B+7.2%

Jade BiosciencesJBIO

$638.62M—

Vera TherapeuticsVERA

$2.83B+85.0%

Eton Pharmaceuticals, Inc.ETON

$684.98M+89.8%

Viridian Therapeutics, Inc.VRDN

$1.98B+79.5%

ANI PharmaceuticalsANIP

$1.82B+17.9%

FAQ

What is Travere Therapeutics, Inc.'s enterprise value?

Travere Therapeutics, Inc. (TVTX) reported enterprise value of $2.68B in Q1 2026.

How has Travere Therapeutics, Inc.'s enterprise value changed year-over-year?

Travere Therapeutics, Inc.'s enterprise value increased by 65.5% year-over-year, from $1.62B to $2.68B.

What is the long-term trend for Travere Therapeutics, Inc.'s enterprise value?

Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s enterprise value has grown at a 17.6% compound annual growth rate (CAGR), from $1.48B to $3.34B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.